Showing 1401-1410 of 1717 results for "".
- Novel Proteomics Study Shows New Evidence of Association between NfL and MS Progression along with 11 CSF Proteins Associated with Long-Term MS Disabilityhttps://practicalneurology.com/news/novel-proteomics-study-shows-new-evidence-of-association-between-nfl-and-ms-progression-along-with-11-csf-proteins-associated-with-long-term-ms-disability/2470334/Analysis from a proteomics study published in Nature Communications revealed that neurofilament light chain (NfL) was the most powerful predictor of multiple sclerosis (MS) activity and a combination of 11 cerebrospinal fluid (CSF) proteins was useful in predicting long-term MS disabilit
- Sevasemten for Becker Muscular Dystrophy Associated with Stabilized Ambulatory Functionhttps://practicalneurology.com/news/sevasemten-for-becker-muscular-dystrophy-associated-with-stabilized-ambulatory-function/2486089/
- Missed Diagnostic Opportunities Common Among Patients With Pregnancy-Associated Strokehttps://practicalneurology.com/news/missed-diagnostic-opportunities-found-to-be-common-among-patients-with-pregnancy-associated-stroke/2485649/More than 1 in 4 pregnant or postpartum individuals with acute stroke experienced a missed diagnostic opportunity (MDO), according to a retrospective multicenter study published in Stroke. The findings highlight frequent diagnostic delays, which according to the study authors, suggest th
- Risk of Adult-Onset MS Associated with Maternal Pregnancy Outcomes in Studyhttps://practicalneurology.com/news/risk-of-adult-onset-ms-associated-with-maternal-pregnancy-outcomes-in-study/2485407/Individuals born large for their gestational age or exposed to maternal diabetes during pregnancy may have an increased risk for developing multiple sclerosis (MS) in adulthood, according to findings from a population-based cohort study published in JAMA Neurology. In contrast, individua
- Cell Therapy for ALS Associated with Increased Survival at 5 Yearshttps://practicalneurology.com/news/cell-therapy-for-als-shows-promise-in-increasing-survival-at-five-years/2475217/Nine out of 10 people with amyotrophic lateral sclerosis (ALS) treated with NurOwn (autologous mesenchymal stem cells [MSC]–neurotrophic factors [NTF]; BrainStorm Cell Therapeutics, New York, NY) survived more than 5 years after symptom onset. These results from an analysis of survival data from
- NMOSD Drug Associated with Favorable Outcomes in Individuals with Generalized Myasthenia Gravishttps://practicalneurology.com/news/study-finds-nmosd-drug-associated-with-favorable-outcomes-in-individuals-with-generalized-myasthenia-gravis/2473963/
- For People with Migraine, Neck Pain is Associated with Greater Disease Burdenhttps://practicalneurology.com/news/for-people-with-migraine-neck-pain-is-associated-with-greater-disease-burden/2470931/People with migraine who experience neck pain during or before headache reported more severe disease burden, according to results of a prospective, cross-sectional, web-based study. The findings, which were presented at the 18th annual European Headache Congress, may have implications for headach
- Update on Risk of PML Infection Associated with Tysabri Presented at CMSC 2024https://practicalneurology.com/news/update-on-risk-of-pml-infection-associated-with-tysabri-presented-at-cmsc-2024/2470482/Promising results from the Tysabri Outread: Unified Commitment to Health (TOUCH) Prescribing Program were reported at the 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). Researchers found that, although cases of progressive multifocal leukoencephalopathy (PML) associat
- Ingrezza Treatment Associated with Sustained Improvements in Patients with Tardive Dyskinesiahttps://practicalneurology.com/news/ingrezza-treatment-associated-with-sustained-improvements-in-patients-with-tardive-dyskinesia/2470477/Results of a post hoc analysis of the KINECT-4 study showed that the majority of participants with tardive dyskinesia (TD) who completed 48 weeks of once-daily Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) treatment experienced clinically meaningful and sustained TD improvements.
- Novel Tau-Targeting Medication for Alzheimer Disease Associated with Sustained Cognitive Benefithttps://practicalneurology.com/news/novel-tau-targeting-medication-for-alzheimer-disease-associated-with-reduced-blood-nfl-improved-cognition/2470424/People diagnosed with early Alzheimer disease (AD) who were treated with the oral tau aggregation inhibitor HMTM (hydromethylthionine mesylate; TauRx Pharmaceuticals, Aberdeen, United Kingdom) showed improvements in standard cognitive and functional outcomes according to research presented at the